FDA warning letter

NuScience Peptides FDA warning letter: what it says

nusciencepeptides.com · Updated 20 October 2026

On 24 August 2026 the FDA's Center for Drug Evaluation and Research sent a warning letter by email to NuScience Peptides LLC, of Cornelius, North Carolina, about its website, nusciencepeptides.com. The letter says it follows a review of the site in July 2026.

According to the letter, the FDA considers nine of the store's products to be unapproved new drugs: three sold under GLP names, among them retatrutide, plus survodutide, mazdutide, PT-141 (bremelanotide), tesamorelin, a tesamorelin and ipamorelin blend, and bacteriostatic water. It says that introducing them into interstate commerce violates the Federal Food, Drug, and Cosmetic Act.

As evidence the letter quotes the store's product pages, which discuss the peptides in connection with obesity, type 2 diabetes, fatty liver disease, muscle wasting, memory and sexual function, and a PubChem page on semaglutide that one product page linked to. It treats the bacteriostatic water as a drug too, because, in the FDA's view, the store sold it to reconstitute peptides meant for injection.

The letter notes that the store labelled its products for laboratory and research use and not for human or veterinary use. It says that, despite those labels, the website shows the products are intended as drugs for human use, pointing also to a peptide calculator offered alongside the bacteriostatic water.

The letter asks the company to reply within 15 business days of receiving it, with the steps it has taken to correct the violations it describes, or with any information showing its products are not in violation. It says that failing to address them could lead to regulatory or legal action without further notice, including seizure and injunction.

Timeline

July 2026
The FDA reviews the store's website, according to the letter.^[1]
24 August 2026
The FDA sends the warning letter by email. It names nine products as unapproved new drugs and asks for a written reply within 15 business days of receipt.^[1]

What this means for buyers

A warning letter sets out the FDA's view of what it found. It is not a court ruling, and the FDA says a company that disagrees can send its reasons and supporting information.
The FDA says this letter came from a review of the store's website. The letter does not report a test of any product.
The FDA posts its warning letters on fda.gov. It may later send a close-out letter, once it has verified that a company has corrected the problems a letter raised. Check there for anything newer than this page.
This page is about the store at nusciencepeptides.com. Check the web address before you pay.
The prices below come from stores in our index. A price listing is not a test of the product.

Our directory keeps a record of this vendor: NuScience Peptides.

Sources

1. Warning letter to NuScience Peptides LLC (MARCS-CMS 733652). U.S. Food and Drug Administration, published 24 August 2026.Supports: The letter's date and recipient, the July 2026 review of the website, the nine products the FDA calls unapproved new drugs, the claims it quotes, its reasons for treating the bacteriostatic water as a drug, its note on the store's research-use labels, the 15-business-day reply and the warning of further action.
2. About Warning and Close-Out Letters. U.S. Food and Drug Administration, published 20 March 2024.Supports: A warning letter sets out what the FDA believes are significant violations, and the recipient can answer it, including with its reasons for disagreeing. A close-out letter may follow once the FDA has verified corrections.

Archived copies are from the Internet Archive. This page reports public records and the companies’ own statements, and claims nothing beyond them. If something here is wrong, tell us.

Current prices for these peptides

The letter names all seven, ipamorelin as part of a tesamorelin blend and semaglutide on a page the store linked to. Below are the three cheapest retail listings in our index for each, cheapest per milligram first. Out-of-stock listings and prices under review are left out, and so is NuScience Peptides.